MedWatch

Lundbeck CEO's pay cut in half in 2020

Lundbeck CEO Deborah Dunsire's salary has been more than halved in 2020, compared with the year before, because Lundbeck gave much higher compensation for Danish taxes on her income in 2019.

Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

Danish pharmaceutical company Lundbeck's top management was rewarded with decent pay raises in 2020, which late in the year cast off significantly more profits than analysts forecast – and more, even, than the same period in the year before.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs